News & Events

Simtra's Head of Development, Lidia Serina, spoke with Contract Pharma about our expansion, the move to unify workstreams across sites, and how we are working to shorten developmental timelines.

Simtra BioPharma Solutions announced that it has formed a five-year strategic alliance with the Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada.

Simtra CCO, James Garrett, discusses the recent sustainability report with BioProcess International, sharing Simtra's commitment to environmental, social, and governance initiatives.

Companies choosing to outsource formulation science should seek a CDMO partner that not only brings expertise beyond what’s available internally but is equally invested in the product’s success.

Simtra BioPharma Solutions nnounces the publication of its inaugural Sustainability Report for the year ended December 31, 2024.

On the latest episode of Drug Digest, Lidia Serina, Ph.D., Head of Development Services at Simtra BioPharma Solutions, discusses three advanced modalities that she believes are shaping the pharmaceutical industry, including antibody-drug conjugates (ADCs) for oncology treatments. 

 

Simtra is driving the future of sterile injectable manufacturing with cutting-edge investments in ADCs, expanded fill-finish capacity, and enhanced development services. As the demand for complex therapies grows, our commitment to quality, efficiency, and patient-centered innovation has never been stronger.

DCAT Week 2025, Lidia Serina, Ph.D., Head of Development Services at Simtra BioPharma Solutions, shares insights into the challenges of maintaining aseptic integrity and stability in sterile injectable manufacturing with BioPharm International.

Simtra BioPharma Solutions expands capabilities with $14M investment for accelerated development and manufacturing of antibody-drug conjugates (ADCs) as part of the scaling of its development services business.